PT  - JOURNAL ARTICLE
AU  - A. Andreu-Bernabeu
AU  - C.M. Díaz-Caneja
AU  - J. Costas
AU  - L. de Hoyos
AU  - C. Stella
AU  - X. Gurriarán
AU  - C. Alloza
AU  - L. Fañanás
AU  - J. Bobes
AU  - A. González Pinto
AU  - B. Crespo-Facorro
AU  - L. Martorell
AU  - E. Vilella
AU  - G. Muntane
AU  - J. Nacher
AU  - M.D. Molto
AU  - E.J. Aguilar
AU  - M. Parellada
AU  - C. Arango
AU  - J. González-Peñas
TI  - Unraveling the relationship of loneliness and isolation in schizophrenia: Polygenic dissection and causal inference
AID  - 10.1101/2020.11.06.20226910
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.06.20226910
4099  - http://medrxiv.org/content/early/2020/11/07/2020.11.06.20226910.short
4100  - http://medrxiv.org/content/early/2020/11/07/2020.11.06.20226910.full
AB  - There is increasing recognition of the association between loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate significant LNL-ISO polygenic score prediction on schizophrenia in an independent case-control sample (N=3,488). We then dissect schizophrenia predisposing variation into subsets of variants based on their effect on LNL-ISO. Genetic variation with concordant effects in both phenotypes show significant SNP-based heritability enrichment, higher polygenic predictive ability in females and positive covariance with other mental disorders such as depression, anxiety, attention-deficit hyperactivity, alcohol use disorder, and autism. Conversely, genetic variation with discordant effects is only predictive in males and negatively correlated with those disorders. This correlation pattern is not observed for bipolar and obsessive-compulsive disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia. These results illustrate the genetic footprint of LNL-ISO on schizophrenia and suggest its role as a potential target for early intervention.Competing Interest StatementDr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Crespo-Facorro has received honoraria (advisory board and educational lectures) and travel expenses from Takeda, Menarini, Angelini, Teva, Otsuka, Lundbeck and Johnson & Johnson. He has also received unrestricted research grants from Lundbeck. Dr. Diaz-Caneja has received honoraria from AbbVie, Sanofi, and Exeltis. Funding StatementThis work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, A way of making Europe, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundacion Familia Alonso, Fundacion Alicia Koplowitz and Fundacion Mutua Madrilena. C. M. Diaz-Caneja holds a Juan Rodes Grant from Instituto de Salud Carlos III (JR19/00024). Xaquin Gurriaran has received a grant from Fundacion Instituto Roche Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Access to human genomic data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. NIH expects that, through Data Access Request (DAR) process, approved users of controlled-access datasets recognize any restrictions on data use established by the Submitting Institutions through the Institutional Certification, and as stated on the dbGaP study page. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in Psychiatric Genomics Consortium website at https://www.med.unc.edu/pgc/download-results/, in Social Science Genetic Association Consortium at https://www.thessgac.org/data and Elucidating the genetic basis of social interaction and isolation at https://doi.org/10.1038/s41467-018-04930-1